Kintor Pharmaceutical Limited
KNTPF
$0.3643
$0.034910.60%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 176.35% | 48.95% | -- | -- | -- |
| Gross Profit | -54.22% | 73.70% | -- | -- | -- |
| SG&A Expenses | -8.69% | -32.09% | -49.25% | -44.27% | -39.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -156.09% | 8.75% | 87.46% | 65.82% | 35.27% |
| Total Operating Expenses | -85.31% | -39.35% | 29.63% | 11.23% | -1.41% |
| Operating Income | 85.80% | 39.65% | -29.63% | -11.23% | 1.41% |
| Income Before Tax | 85.52% | 37.67% | -37.86% | -18.27% | -4.69% |
| Income Tax Expenses | 100.22% | -0.29% | -1,383.09% | -1,013.23% | -816.18% |
| Earnings from Continuing Operations | 85.41% | 37.83% | -36.63% | -17.24% | -3.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 85.41% | 37.83% | -36.63% | -17.24% | -3.79% |
| EBIT | 85.80% | 39.65% | -29.63% | -11.23% | 1.41% |
| EBITDA | 86.90% | 40.18% | -30.54% | -11.49% | 1.48% |
| EPS Basic | 85.44% | 39.57% | -27.22% | -4.99% | 9.38% |
| Normalized Basic EPS | 85.56% | 40.92% | -21.60% | -0.84% | 12.62% |
| EPS Diluted | 85.44% | 39.57% | -27.22% | -4.99% | 9.38% |
| Normalized Diluted EPS | 85.56% | 40.92% | -21.60% | -0.84% | 12.62% |
| Average Basic Shares Outstanding | 0.39% | 2.84% | 5.42% | 9.51% | 13.94% |
| Average Diluted Shares Outstanding | 0.39% | 2.84% | 5.42% | 9.51% | 13.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |